UBS analyst Eliana Merle initiated coverage of Tyra Biosciences (TYRA) with a Buy rating and $28 price target Tyra Biosciences is a clinical-stage biotech company with a drug, TYRA-300 ...

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology.